MicroRNAs as new therapeutic targets and tools in cancer

Paolo Gandellini, Valentina Profumo, Marco Folini, Nadia Zaffaroni

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Introduction: MicroRNAs (miRNAs) are a class of endogenous, non-coding small RNAs that negatively regulate gene expression at the post-transcriptional level. Several studies have provided evidence that abnormal expression of selected miRNAs is associated with the pathogenesis of cancer. As they can act as either oncogenes or tumor suppressors, miRNAs have been proposed as potential new therapeutic targets or tools for cancer therapy. Areas covered: This paper reviews a significant body of the experimental data collected to date which indicate that specific miRNA inhibition or replacement can successfully modify the proliferative and invasive properties of tumor cells. It discusses recent evidence that has also revealed a direct involvement of miRNAs in drug resistance, underlying an entirely new mechanism by which tumor cells may be refractory to the treatment with cytotoxic agents. Based on these findings, in the therapeutic setting, interference with cancer-specific miRNAs could be exploited not only to produce a direct anticancer effect but also to improve the response of tumor cells to conventional treatments. Expert opinion: Overall, manipulation of miRNA functions, either by mimicking or inhibiting them, is emerging as a highly promising therapeutic strategy. However, before miRNA-based therapeutics enters the clinical armamentarium, important issues concerning specific delivery to cells/tissues of interest, safety as well as pharmacokinetic profiles needs to be addressed.

Original languageEnglish
Pages (from-to)265-279
Number of pages15
JournalExpert Opinion on Therapeutic Targets
Volume15
Issue number3
DOIs
Publication statusPublished - Mar 2011

Fingerprint

MicroRNAs
Tumors
Neoplasms
Cells
Therapeutics
Small Untranslated RNA
Pharmacokinetics
Cytotoxins
Expert Testimony
Oncogenes
Drug Resistance
Gene expression
Refractory materials
Tissue
Safety
Gene Expression
Pharmaceutical Preparations

Keywords

  • Adenovirus
  • Antagomir
  • Cancer
  • Drug response
  • Locked nucleic acid
  • microRNA
  • miRNA replacement

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

MicroRNAs as new therapeutic targets and tools in cancer. / Gandellini, Paolo; Profumo, Valentina; Folini, Marco; Zaffaroni, Nadia.

In: Expert Opinion on Therapeutic Targets, Vol. 15, No. 3, 03.2011, p. 265-279.

Research output: Contribution to journalArticle

@article{95d9d21d39794cef8e3576c747aa2ed5,
title = "MicroRNAs as new therapeutic targets and tools in cancer",
abstract = "Introduction: MicroRNAs (miRNAs) are a class of endogenous, non-coding small RNAs that negatively regulate gene expression at the post-transcriptional level. Several studies have provided evidence that abnormal expression of selected miRNAs is associated with the pathogenesis of cancer. As they can act as either oncogenes or tumor suppressors, miRNAs have been proposed as potential new therapeutic targets or tools for cancer therapy. Areas covered: This paper reviews a significant body of the experimental data collected to date which indicate that specific miRNA inhibition or replacement can successfully modify the proliferative and invasive properties of tumor cells. It discusses recent evidence that has also revealed a direct involvement of miRNAs in drug resistance, underlying an entirely new mechanism by which tumor cells may be refractory to the treatment with cytotoxic agents. Based on these findings, in the therapeutic setting, interference with cancer-specific miRNAs could be exploited not only to produce a direct anticancer effect but also to improve the response of tumor cells to conventional treatments. Expert opinion: Overall, manipulation of miRNA functions, either by mimicking or inhibiting them, is emerging as a highly promising therapeutic strategy. However, before miRNA-based therapeutics enters the clinical armamentarium, important issues concerning specific delivery to cells/tissues of interest, safety as well as pharmacokinetic profiles needs to be addressed.",
keywords = "Adenovirus, Antagomir, Cancer, Drug response, Locked nucleic acid, microRNA, miRNA replacement",
author = "Paolo Gandellini and Valentina Profumo and Marco Folini and Nadia Zaffaroni",
year = "2011",
month = "3",
doi = "10.1517/14728222.2011.550878",
language = "English",
volume = "15",
pages = "265--279",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - MicroRNAs as new therapeutic targets and tools in cancer

AU - Gandellini, Paolo

AU - Profumo, Valentina

AU - Folini, Marco

AU - Zaffaroni, Nadia

PY - 2011/3

Y1 - 2011/3

N2 - Introduction: MicroRNAs (miRNAs) are a class of endogenous, non-coding small RNAs that negatively regulate gene expression at the post-transcriptional level. Several studies have provided evidence that abnormal expression of selected miRNAs is associated with the pathogenesis of cancer. As they can act as either oncogenes or tumor suppressors, miRNAs have been proposed as potential new therapeutic targets or tools for cancer therapy. Areas covered: This paper reviews a significant body of the experimental data collected to date which indicate that specific miRNA inhibition or replacement can successfully modify the proliferative and invasive properties of tumor cells. It discusses recent evidence that has also revealed a direct involvement of miRNAs in drug resistance, underlying an entirely new mechanism by which tumor cells may be refractory to the treatment with cytotoxic agents. Based on these findings, in the therapeutic setting, interference with cancer-specific miRNAs could be exploited not only to produce a direct anticancer effect but also to improve the response of tumor cells to conventional treatments. Expert opinion: Overall, manipulation of miRNA functions, either by mimicking or inhibiting them, is emerging as a highly promising therapeutic strategy. However, before miRNA-based therapeutics enters the clinical armamentarium, important issues concerning specific delivery to cells/tissues of interest, safety as well as pharmacokinetic profiles needs to be addressed.

AB - Introduction: MicroRNAs (miRNAs) are a class of endogenous, non-coding small RNAs that negatively regulate gene expression at the post-transcriptional level. Several studies have provided evidence that abnormal expression of selected miRNAs is associated with the pathogenesis of cancer. As they can act as either oncogenes or tumor suppressors, miRNAs have been proposed as potential new therapeutic targets or tools for cancer therapy. Areas covered: This paper reviews a significant body of the experimental data collected to date which indicate that specific miRNA inhibition or replacement can successfully modify the proliferative and invasive properties of tumor cells. It discusses recent evidence that has also revealed a direct involvement of miRNAs in drug resistance, underlying an entirely new mechanism by which tumor cells may be refractory to the treatment with cytotoxic agents. Based on these findings, in the therapeutic setting, interference with cancer-specific miRNAs could be exploited not only to produce a direct anticancer effect but also to improve the response of tumor cells to conventional treatments. Expert opinion: Overall, manipulation of miRNA functions, either by mimicking or inhibiting them, is emerging as a highly promising therapeutic strategy. However, before miRNA-based therapeutics enters the clinical armamentarium, important issues concerning specific delivery to cells/tissues of interest, safety as well as pharmacokinetic profiles needs to be addressed.

KW - Adenovirus

KW - Antagomir

KW - Cancer

KW - Drug response

KW - Locked nucleic acid

KW - microRNA

KW - miRNA replacement

UR - http://www.scopus.com/inward/record.url?scp=79951586929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951586929&partnerID=8YFLogxK

U2 - 10.1517/14728222.2011.550878

DO - 10.1517/14728222.2011.550878

M3 - Article

C2 - 21208133

AN - SCOPUS:79951586929

VL - 15

SP - 265

EP - 279

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 3

ER -